Clinical Trials Browser

Phase 3 × Has results × Papillomavirus Infections × Clear all

NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Phase 3 Completed

165 enrolled 13 charts

COVID-19, Papillomavirus Infections

NCT01302834 2026-01-12

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Phase 3 Completed

987 enrolled 59 charts

Head & NeckOther neoplasm

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Precancerous Conditions, Papillomavirus Infections

NCT04772534 2025-05-30

V503-066

Phase 3 Completed

314 enrolled 12 charts

Papillomavirus Infections

NCT02135419 2024-07-26

ANCHOR

Phase 3 Completed

4,446 enrolled 13 charts

GastrointestinalGynecologic

Squamous Intraepithelial Lesions, Acquired Immunodeficiency Syndrome, Anus Neoplasms, HIV Infections, Papillomavirus Infections

NCT00380367 2023-05-31

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Phase 3 Completed

110 enrolled 7 charts

Papillomavirus Infections

NCT00943722 2022-10-03

A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)

Phase 3 Completed

3,074 enrolled 24 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00481767 2020-11-17

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.

Phase 3 Completed

676 enrolled 15 charts

Infections, Papillomavirus Infections

NCT00947115 2020-10-30

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

Phase 3 Completed

525 enrolled 24 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01164722 2020-08-04

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

Phase 3 Completed

120 enrolled 13 charts

GastrointestinalGynecologicOther neoplasm

Squamous Intraepithelial Lesions, Anus Neoplasms, Precancerous Conditions, HIV Infections, Papillomavirus Infections

NCT01381575 2020-06-09

Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls

Phase 3 Completed

1,447 enrolled 26 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01627561 2020-04-10

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

Phase 3 Completed

148 enrolled 28 charts

Papillomavirus Infections

NCT03546842 2020-02-25

V503-017

Phase 3 Completed

201 enrolled 11 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections, Adenocarcinoma in Situ

NCT00877877 2020-01-18

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.

Phase 3 Completed

632 enrolled 28 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00637195 2020-01-03

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

Phase 3 Completed

152 enrolled 21 charts

Uterine Cervical Neoplasms, Hepatitis B, Papillomavirus Infections

NCT00250276 2020-01-02

Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.

Phase 3 Completed

798 enrolled 19 charts

Papillomavirus Infections

NCT00294047 2020-01-02

Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Phase 3 Completed

5,752 enrolled 42 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00423046 2020-01-02

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Phase 3 Completed

1,106 enrolled 27 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT03158220 2019-11-21

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Phase 3 Completed

1,212 enrolled 15 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT01462357 2019-11-15

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Phase 3 Completed

1,079 enrolled 26 charts

Papillomavirus Infections

NCT01249365 2019-11-13

The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Phase 3 Completed

199 enrolled 9 charts

Papillomavirus Infections

NCT01190176 2019-10-30

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

Phase 3 Completed

34 enrolled 12 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00937950 2019-10-29

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

Phase 3 Completed

2,022 enrolled 10 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01190189 2019-06-19

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Phase 3 Completed

137 enrolled 9 charts

Papillomavirus Infections

NCT00834106 2019-02-04

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

Phase 3 Completed

3,006 enrolled 17 charts

Papillomavirus Infections

NCT00988884 2018-12-14

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Phase 3 Completed

1,241 enrolled 15 charts

Papillomavirus Infections

NCT01254643 2018-11-28

A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).

Phase 3 Completed

100 enrolled 8 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01073293 2018-11-27

A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)

Phase 3 Completed

1,054 enrolled 15 charts

Papillomavirus Infections

NCT01245764 2018-11-14

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Phase 3 Completed

250 enrolled 20 charts

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT02114385 2018-11-01

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Phase 3 Completed

500 enrolled 14 charts

Papillomavirus Infections

NCT00492544 2018-09-04

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Phase 3 Completed

100 enrolled 9 charts

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00122681 2018-08-20

Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Phase 3 Completed

18,729 enrolled 35 charts

Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

814 enrolled 28 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

744 enrolled 27 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00996125 2018-08-17

Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects

Phase 3 Completed

750 enrolled 12 charts

Papillomavirus Infections

NCT01277042 2018-08-17

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

Phase 3 Completed

1,212 enrolled 14 charts

Papillomavirus Infections

NCT01984697 2018-08-08

V503-010

Phase 3 Completed

1,518 enrolled 44 charts

Papillomavirus Infections

NCT00344032 2018-07-20

Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women

Phase 3 Completed

354 enrolled 12 charts

Papillomavirus Infections

NCT00345878 2018-07-20

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Phase 3 Completed

271 enrolled 12 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00369824 2018-07-20

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

Phase 3 Completed

1,330 enrolled 25 charts

Meningitis, Tetanus, Whooping Cough, Papillomavirus Infections

NCT00426361 2018-07-20

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

Phase 3 Completed

751 enrolled 22 charts

Papillomavirus Infections

NCT00485732 2018-07-20

A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years

Phase 3 Completed

225 enrolled 14 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00799825 2018-07-12

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Phase 3 Completed

346 enrolled 8 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01418937 2018-07-12

Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study

Phase 3 Completed

164 enrolled 8 charts

Papillomavirus Infections

NCT00552279 2018-06-25

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Phase 3 Completed

805 enrolled 16 charts

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00092547 2018-02-20

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Phase 3 Completed

1,781 enrolled 32 charts

Papillomavirus Infections

NCT00090220 2017-04-21

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Phase 3 Completed

3,819 enrolled 34 charts

Papillomavirus Infections

NCT00496626 2017-04-17

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Phase 3 Completed

600 enrolled 12 charts

Papillomavirus Infections

NCT00973362 2017-01-06

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

Phase 3 Completed

12,896 enrolled 11 charts

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections, Atypical Squamous Cells of the Cervix

NCT00456807 2016-12-16

Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years

Phase 3 Completed

100 enrolled 10 charts

Papillomavirus Infections

NCT00811798 2016-10-20

Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.

Phase 3 Completed

92 enrolled 6 charts

Papillomavirus Infections